Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japanese Regulators Recommend Wyeth-Pfizer's Torisel And Celgene's Revlimid For Approval

This article was originally published in PharmAsia News

Executive Summary

The Second Committee on New Drugs at Japan's Ministry of Health, Labor and Welfare on May 31 recommended Wyeth-Pfizer's Torisel (temsirolimus) and Celgene's Revlimid (lenalidomide) for approval. The approvals came with post-market surveillance requirements and a restricted distribution system in the case of Revlimid

You may also be interested in...



Pfizer, Wyeth Japan Subsidiaries Merge To Become Second-largest Pharma

TOKYO - Pfizer Japan and Wyeth Japan, both of them fully owned by their U.S. parent firms, announced their merger, effective June 1, becoming Japan's second-largest pharmaceutical manufacturer after Takeda Pharmaceutical Co. and expanding Pfizer Japan's cardio and neural product lineup with Wyeth's vaccines

Pfizer Halts Sutent's Phase III in Hepatocellular Carcinoma

Failure is the second in two months for Sutent, which is a lynchpin of Pfizer's oncology strategy.

Pfizer Reports Sutent Safe And Effective In Asians; Forges Alliances With Major Asian Oncology Centers

PERTH, Australia - Pfizer Sept. 21 released data on a Phase IIIb Asian trial of its leading oncology drug multi-kinase inhibitor Sutent, which demonstrated similar effectiveness and tolerability in Asians as in non-Asians

UsernamePublicRestriction

Register

SC066183

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel